Analysis of risk factors for parenteral nutrition-associated cholestasis in preterm infants: a multicenter observational study

Table 4 Comparison of preterm complications of patients between the two groups

	Non-PNAC (n = 384)	PNAC (n = 81)	Z/T/χ ²	P
RDS (n, %)	233(60.7)	63(77.8)	8.455	0.004
hsPDA (n, %)	209(54.4)	56(69.1)	5.904	0.015
EOS (n, %)	25(6.5)	9(11.1)	2.089	0.148
NEC ≥ stage II (n, %)	17(4.4)	11(13.6)	8.352	0.004*
Surgically treated NEC	5(1.3)	8(9.9)	15.079	<0.001*
LOS (n, %)	66(17.2)	22(27.2)	4.336	0.037
Brain injury (n, %)	137(35.7)	29(35.8)	<0.001	0.983
ROP with intervention (n, %)	13(3.4)	4(4.9)	0.123	0.726*
Moderate/severe BPD (n, %)	77(20.1)	16(19.8)	0.004	0.951
MBDP (n, %)	8(2.1)	10(12.3)	16.274	<0.001*
EUGR (n, %)	199(51.8)	62(76.5)	16.600	<0.001

*Continuity correction chi square test. PNAC, parenteral nutrition-associated cholestasis; RDS, respiratory distress syndrome; hsPDA, hemodynamically significant patent ductus arteriosus; EOS, early-onset sepsis; NEC, necrotizing enterocolitis; LOS, late-onset sepsis; ROP, retinopathy of prematurity; BPD, bronchopulmonary dysplasia; MBDP, metabolic bone disease of prematurity; EUGR, extrauterine growth retardation

ISSN: 1471-2431